Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Clinigence Holdings ( (NUTX) ) is now available.
At the annual meeting of stockholders of Nutex Health Inc. held on July 14, 2025, several key decisions were made. All seven director nominees were elected for a one-year term, the compensation of executive officers was approved, an amendment to the 2023 Equity Incentive Plan was passed, and Grant Thornton LLP was ratified as the independent accounting firm for 2025.
The most recent analyst rating on (NUTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Outperform.
Nutex Health’s strong financial performance and impressive earnings call results are the most significant contributors to the overall score. The company’s solid revenue growth, profitability improvements, and strategic expansion plans indicate a promising outlook. The technical indicators suggest some caution, but the undervaluation based on the P/E ratio enhances the stock’s attractiveness.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 195,494
Technical Sentiment Signal: Hold
Current Market Cap: $644.7M
Find detailed analytics on NUTX stock on TipRanks’ Stock Analysis page.